Analyst Estimates: Here's What Brokers Think Of Simcere Pharmaceutical Group Limited (HKG:2096) After Its Yearly Report
Investors in Simcere Pharmaceutical Group Limited (HKG:2096) had a good week, as its shares rose 2.9% to close at HK$5.30 following the release of its full-year results. Results were roughly in
Xiansheng Pharmaceutical (02096.HK) spent HK$9.5 million to buy back 1.816 million shares on April 25
Gelonghui, April 25 | Xiansheng Pharmaceutical (02096.HK) announced that it spent HK$9.5 million to buy back 1.816 million shares on April 25.
Simcere Pharmaceutical' Profit Down 23% in 2023
Simcere Pharmaceutical Group (HKG:2096) recorded a 23% decline in attributable profit for the year ended Dec. 31, 2023, to 714.8 million yuan from 930.9 million yuan during the year-ago period, accord
先聲藥業:2023年度報告
Xiansheng Pharmaceutical (02096) spent HK$2,955,400 to buy back 566,000 shares on April 24
According to the Zhitong Finance App, Xiansheng Pharmaceutical (02096) announced that on April 24, 2024, the company spent HK$2,955,400 to repurchase 566,000 shares, with a repurchase price of HK$5.21-5.24 per share.
Zhitong Hong Kong Stock Repurchase Statistics|April 24
Hong Kong Stock Repurchase Statistics|April 24
Xiansheng Pharmaceutical (02096.HK) spent HK$4.5821 million to buy back 880,000 shares on April 23
Gelonghui, April 23, 丨 Xiansheng Pharmaceutical (02096.HK) issued an announcement. On April 23, 2024, it spent HK$4.5821 million to repurchase 880,000 shares at a repurchase price of HK$5.19-5.23 per share.
Xiansheng Pharmaceutical (02096.HK) spent HK$4.85,700 to buy back 930,000 shares on April 22
Gelonghui, April 22, 丨 Xiansheng Pharmaceutical (02096.HK) issued an announcement. On April 22, 2024, it spent HK$4.85,700 to repurchase 930,000 shares, with a repurchase price of HK$5.2-5.25 per share.
On April 19, Xiansheng Pharmaceutical spent HK$15.52 million to repurchase 2.92 million shares
Xiansheng Pharmaceutical (02096) announced that on April 19, 2024, the company spent HK$15.52 million to repurchase 2.92 million shares, with a repurchase price of HK$5.1-5.17 per share.
Xiansheng Pharmaceutical (02096.HK) spent HK$1.515 million to repurchase 2.92 million shares on April 19
Gelonghui, April 21, 丨 Xiansheng Pharmaceutical (02096.HK) issued an announcement. On April 19, 2024, it spent HK$1.515 million to repurchase 2.92 million shares at a repurchase price of HK$5.1-5.17 per share.
[Broker Focus] Zheshang Securities maintains Xiansheng Pharmaceutical's (02096) “buy” rating and is optimistic about the company's profit improvement
Jinwu Financial News | Zheshang Securities released a research report that Xiansheng Pharmaceutical (02096) achieved revenue of 6.608 billion yuan (RMB, same unit) in 2023, up 4.5% year on year, in line with market expectations; achieved net profit of 715 million yuan, down 23.2% year on year, which is mainly due to the large investment income base in 2022. By business, there is a clear trend that the company's share of innovative drug revenue will continue to rise in 2023. We are optimistic about the company's innovative drug sector revenue in 2024-2025. According to the bank, the company's gross margin in 2023 was 75.4%, down 3.6% year on year, mainly
Xiansheng Pharmaceutical (02096.HK) spent HK$13.2969 million to repurchase 2.569 million shares on April 18
Gelonghui, April 18, 丨 Xiansheng Pharmaceutical (02096.HK) issued an announcement. On April 18, 2024, it spent HK$13.296,900 to repurchase 2.569 million shares at a repurchase price of HK$5.14-5.21 per share.
Xiansheng Pharmaceutical (02096) spent HK$16.948,200 to buy back 3.288 million shares on April 17
Xiansheng Pharmaceutical (02096) announced that it spent HK$16.948,200 to buy back 328 on April 17, 2024...
Xiansheng Pharmaceutical (02096.HK) spent HK$19.611 million to buy back 3.81 million shares on April 16
Gelonghui, April 16, 丨 Xiansheng Pharmaceutical (02096.HK) issued an announcement. On April 16, 2024, it spent HK$19.611 million to repurchase 3.81 million shares at a repurchase price of HK$5.11-5.21 per share.
Xiansheng Pharmaceutical (02096) spent HK$19.611 million to buy back 3.81 million shares on April 16
Xiansheng Pharmaceutical (02096) announced that on April 16, 2024, the company spent HK$19611 million...
Xiansheng Pharmaceutical (02096) spent about HK$15.23 million to repurchase 2.885 million shares on April 15
Xiansheng Pharmaceutical (02096) announced that on April 15, 2024, it cost approximately HK$15.23 million to repurchase 288...
Xiansheng Pharmaceutical (02096) spent HK$10.9087 million to buy back 2.08 million shares on April 12
Xiansheng Pharmaceutical (02096) announced that on April 12, 2024, the company spent 10.9087 million...
Xiansheng Pharmaceutical (02096) spent about HK$7.881,000 to buy back 1.47 million shares on April 10
Xiansheng Pharmaceutical (02096) announced that on April 10, 2024, it cost approximately HK$7.881 million to repurchase 147...
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA
Simcere Pharmaceutical Group (HKG:2096) said its new investigational anti-tumor drug has been granted a Fast Track Designation by the U.S. Food and Drug Administration for multiple myeloma patients, a
Xiansheng Pharmaceutical (02096.HK) injectable SIM0500 (humanized GPRC5D-BCMA-CD3 trispecific antibody) was awarded US Food and Drug Administration Fast Track Qualification
Gelonghui, April 9, 丨 Xiansheng Pharmaceutical (02096.HK) announced that on April 9, 2024, Beijing time, the group's self-developed new anti-tumor drug, SIM0500, a humanized GPRC5D-BCMA-CD3 tri-specific antibody injection, was granted a fast-track qualification by the US Food and Drug Administration (“FDA”) to be used for previous treatment with ≥3 lines of treatment (including a proteasome inhibitor (PI), an immunomodulator (IMID), and an anti-CD38 monoclonal antibody), and is known to provide clinical benefits standards Treating drug-resistant or intolerable
No Data